CAHCardinal Health
Is the business good?
A genuinely good business: 7 of 9 health tests passed, earnings fully cash-backed (3.3×), and margins widening.
High fundamental quality. Nine pass/fail tests of year-over-year health from the filings.
Operating profit is fully backed by cash. Conversion is improving vs a year ago.
Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is CAH?
Cardinal Health earns 59% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
Return on invested capital · cost of capital 9.0% · 50 points above what the capital costs: growth creates value
- Operating margin
- 1.0%
Operating margin · Healthcare median 0.97% · 12 months to Q2 2026
- Cash conversion
- 3.27×
Cash conversion · 0.01× a year ago · operating cash flow covers the operating profit after tax
- Share count, year on year
- −2.5%
Share count, year on year · bought back, each share owns more of the company
| Year | Operating margin |
|---|---|
| FY2021 | 0.29% |
| FY2022 | −0.33% |
| FY2023 | 0.37% |
| FY2024 | 0.55% |
| FY2025 | 1.0% |
| FY2026 | 1.0% |
Details›
- Gross margin12 months to Q2 2026
- 3.7%
- Operating margin12 months to Q2 2026
- 1.0%
- Net margin12 months to Q2 2026
- 0.68%
- Free cash flow margin
- 2.3%
- Revenue, trailing twelve months
- $244.7B
- Free cash flow, trailing twelve months
- $5.50B
- Net income, trailing twelve months
- $1.66B
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 59%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from CAH and who it buys from, as the companies report it.
- CVSCVS Health28%
Share of revenue · FY2026 10-K
- PCRXPacira BioSciences, Inc.26%
CAH is 26% of its revenue · FY2025 10-K
- AMPHAmphastar Pharmaceuticals, Inc.19%
CAH is 19% of its revenue · FY2025 10-K
- ALKSAlkermes plc17%
CAH is 17% of its revenue · FY2025 10-K
- BHCBausch Health Companies Inc.14%
CAH is 14% of its revenue · FY2025 10-K
- PFEPfizer13%
CAH is 13% of its revenue · FY2025 10-K
- MRNAModerna11%
CAH is 11% of its revenue · FY2025 10-K
A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; CAH’s own figures are from its FY2026 10-K. Smaller customers and suppliers go unreported.
Healthcare
Ranks #79 of 436 by RyuScore